Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone;Leucémies aiguës chez deux patients atteints de sclérose en plaques et traités par mitoxantrone

Revue Neurologique

Volumn 162, Issue 2, 2006, Pages 195-199

  Nollet, S ^a   Berger, E ^a   Deconinck, E ^a   Baldauf, E ^b   Rumbach, L ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b Pasteur Hospital   (France)

Author keywords

Leukemia; Mitoxantrone; Multiple sclerosis

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ANAMNESIS; ARTICLE; CASE REPORT; DISEASE COURSE; FEMALE; HUMAN; LABORATORY TEST; LOW DRUG DOSE; MULTIPLE SCLEROSIS; PROMYELOCYTIC LEUKEMIA;

EID: 33645564916     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(06)74999-2     Document Type: Article

References (28)

1. ACHIRON A, BARAK Y, GAIL M, MANDEL M, PEE D, AYYAGARI R, ROTSTEIN Z. (2005). Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat, 89: 265-270.
2. BEAUMONT M, SANZ M, CARLI PM et al. (2003). Therapy-related acute promyelocytic leukemia. J Clin Oncol 21: 2123-2137.
3. BRASSAT D, RECHER C, WAUBANT E et al. (2002). Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology, 59: 954-955.
4. BRONNUM-HANSEN H, KOCH-HENRIKSEN N, STENAGER E. (2004). Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain, 127: 844-850.
5. CASTILLA LH, GARRETT L, ADYA N et al. (1999). The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet, 23: 144-146.
6. CATTANEO C, ALMICI C, BORLENGHI E, MOTTA M, ROSSI G. (2003). A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia, 17: 985-986.
7. DELISSE B, DE SEZE J, MACKOWIAK A et al. (2004). Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. Mult Scler, 10: 92.
8. EDAN G, MILLER D, CLANET M et al. (1997). Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry, 62: 112-118.
9. EDAN G, BROCHET B, CLANET M, LE PAGE E et al. (2004a). Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients: a 4-year mean follow-up study. Neurology, 62(suppl 5): A493.
10. EDAN G, MORISSEY S, LE PAGE E. (2004b). Rationale for the use of mitoxantrone in multiple sclerosis. J Neurol Sci, 223: 35-39.
11. FOX EJ. (2004) Immunopathology of multiple sclerosis. Neurology, 63 (Suppl. 6): S3-S7.
12. GHALIE RG, MAUCH E, EDAN G et al. (2002). A study of therapy-related acute leukemia after mitoxantrone therapy for multiple sclerosis. Mult Scler, 8: 441-445.
13. GRISOLANO JL, WESSELSCHMIDT RL, PELICCI PG, LEY TJ. (1997). Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood, 89: 376-387.
14. HARTUNG HP, GONSETTE R, KONIG N et al. (2002). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet, 360: 2018-2025.
15. HEESEN C, BRUEGMANN M, GBDAMOSI J, KOCH E, MONCH A, BUHMANN C. (2003). Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult Scler, 9: 213-214.
16. HOSSFELD DK. (2000). Mitoxantrone-related acute myelocytic leukemias. Ann Oncol, 11: 1215-1216.
17. LARSON RA, LE BEAU MM, RATAIN MJ, ROWLEY JD. (1992). Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. Blood, 79: 1892-1893.
18. NOVOSELAC AV, REDDY S, SANMUGARAJAH J. (2004). Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone. Leukemia, 18: 1561-1562.
19. PEDERSEN-BJERGAARD J, ANDERSEN MK, CHRISTIANSEN DH, NERLOV C. (2002). Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood, 99: 1909-1912.
20. PEDERSEN-BJERGAARD J, PEDERSEN M, ROULSTON D, PHILIP P. (1995). Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood, 86: 3542-3552.
21. PEDERSEN-BJERGAARD J, PHILIP P. (1991). Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood, 78: 1147-1148.
22. PEDERSEN-BJERGAARD J, PHILIP P, LARSEN SO et al. (1993). Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia, 7: 1975-1986.
23. PEDERSEN-BJERGAARD J, PHILIP P, LARSEN SO, JENSEN G, BYRSTING K. (1990). Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood, 76: 1083-1091.
24. QUESNEL B, KANTARJIAN H, BJERGAARD JP et al. (1993). Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol, 11: 2370-2379.
25. RIDGE SC, SLOBODA AE, MC REYNOLDS RA, LEVINE S, ORONSKY AL, KERWAR SS. (1985). Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol, 35: 35-42.
26. TANASESCU R, DEBOUVERIE M, PITTION S, ANXIONNAT R, VESPIGNANI H. (2004). Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient. J Neurol, 251: 762-763.
27. VICARI AM, CICERI F, FOLLI F, LANZI R, COLOMBO B, COMI G, CAMBA L. (1998). Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia, 12: 441-442.
28. VOLTZ R, STARCK M, ZINGLER V, STRUPP M, KOLB HJ. (2004). Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler, 10: 472-474.